Dacetuzumab, a humanized mAb against CD40 for the treatment of hematological malignancies - PubMed (original) (raw)
Affiliations
- PMID: 19513947
Dacetuzumab, a humanized mAb against CD40 for the treatment of hematological malignancies
Sapna Khubchandani et al. Curr Opin Investig Drugs. 2009 Jun.
Abstract
Dacetuzumab, a humanized mAb targeting the CD40 antigen, is in development by Seattle Genetics Inc and licensee Genentech Inc for the potential treatment of hematological malignancies. The CD40 antigen is a highly expressed cell surface transmembrane protein that is present in normal B-cells. Experiments using blocking antibodies for the CD40 ligand demonstrated that CD40 signaling may play a role in the development and maintenance of B-cell hematological malignancies and some solid tumors. In vitro, dacetuzumab exhibited antitumor activity against several B-cell lymphoma and multiple myeloma (MM) cell lines, and induced direct apoptosis as well as the engagement of effective antibody-dependent cell-mediated cytotoxicity. In vivo, dacetuzumab demonstrated enhanced antitumor efficacy in combination with other mAbs and chemotherapeutic agents; many of these combinations are now being tested clinically. Early clinical trials have evaluated the pharmacokinetics, safety and efficacy of dacetuzumab monotherapy in patients with relapsed/refractory B-cell lymphomas or MM. Targeting CD40 with dacetuzumab resulted in modest antitumor activity in B-cell lymphomas and, to a lesser extent, in MM. In particular, patients with diffuse large B-cell lymphoma responded well to dacetuzumab; the drug is being pursued for this indication in phase II trials.
Similar articles
- Distinct apoptotic signaling characteristics of the anti-CD40 monoclonal antibody dacetuzumab and rituximab produce enhanced antitumor activity in non-Hodgkin lymphoma.
Lewis TS, McCormick RS, Emmerton K, Lau JT, Yu SF, McEarchern JA, Grewal IS, Law CL. Lewis TS, et al. Clin Cancer Res. 2011 Jul 15;17(14):4672-81. doi: 10.1158/1078-0432.CCR-11-0479. Epub 2011 May 24. Clin Cancer Res. 2011. PMID: 21610152 - Preclinical antilymphoma activity of a humanized anti-CD40 monoclonal antibody, SGN-40.
Law CL, Gordon KA, Collier J, Klussman K, McEarchern JA, Cerveny CG, Mixan BJ, Lee WP, Lin Z, Valdez P, Wahl AF, Grewal IS. Law CL, et al. Cancer Res. 2005 Sep 15;65(18):8331-8. doi: 10.1158/0008-5472.CAN-05-0095. Cancer Res. 2005. PMID: 16166310 - Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin's lymphoma.
Advani R, Forero-Torres A, Furman RR, Rosenblatt JD, Younes A, Ren H, Harrop K, Whiting N, Drachman JG. Advani R, et al. J Clin Oncol. 2009 Sep 10;27(26):4371-7. doi: 10.1200/JCO.2008.21.3017. Epub 2009 Jul 27. J Clin Oncol. 2009. PMID: 19636010 Clinical Trial. - Anti-CD40-mediated cancer immunotherapy: an update of recent and ongoing clinical trials.
Hassan SB, Sørensen JF, Olsen BN, Pedersen AE. Hassan SB, et al. Immunopharmacol Immunotoxicol. 2014 Apr;36(2):96-104. doi: 10.3109/08923973.2014.890626. Epub 2014 Feb 21. Immunopharmacol Immunotoxicol. 2014. PMID: 24555495 Review. - Preclinical and clinical evaluation of epratuzumab (anti-CD22 IgG) in B-cell malignancies.
Leonard JP, Goldenberg DM. Leonard JP, et al. Oncogene. 2007 May 28;26(25):3704-13. doi: 10.1038/sj.onc.1210370. Oncogene. 2007. PMID: 17530024 Review.
Cited by
- Immune checkpoint blockade in cancer treatment: a double-edged sword cross-targeting the host as an "innocent bystander".
Gelao L, Criscitiello C, Esposito A, Goldhirsch A, Curigliano G. Gelao L, et al. Toxins (Basel). 2014 Mar 3;6(3):914-33. doi: 10.3390/toxins6030914. Toxins (Basel). 2014. PMID: 24594636 Free PMC article. Review. - Target Therapy in Hematological Malignances: New Monoclonal Antibodies.
Podhorecka M, Markowicz J, Szymczyk A, Pawlowski J. Podhorecka M, et al. Int Sch Res Notices. 2014 Oct 29;2014:701493. doi: 10.1155/2014/701493. eCollection 2014. Int Sch Res Notices. 2014. PMID: 27433507 Free PMC article. Review. - Monoclonal Antibodies for the Treatment of Multiple Myeloma: An Update.
Abramson HN. Abramson HN. Int J Mol Sci. 2018 Dec 7;19(12):3924. doi: 10.3390/ijms19123924. Int J Mol Sci. 2018. PMID: 30544512 Free PMC article. Review. - Autoimmune therapies targeting costimulation and emerging trends in multivalent therapeutics.
Chittasupho C, Siahaan TJ, Vines CM, Berkland C. Chittasupho C, et al. Ther Deliv. 2011 Jul;2(7):873-89. doi: 10.4155/tde.11.60. Ther Deliv. 2011. PMID: 21984960 Free PMC article. Review. - Trial Watch: Immunostimulatory monoclonal antibodies for oncological indications.
Cabo M, Offringa R, Zitvogel L, Kroemer G, Muntasell A, Galluzzi L. Cabo M, et al. Oncoimmunology. 2017 Aug 30;6(12):e1371896. doi: 10.1080/2162402X.2017.1371896. eCollection 2017. Oncoimmunology. 2017. PMID: 29209572 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Research Materials